Latest News Archive

Please select Category, Year, and then Month to display items

UFS helps Tritech National Science and Technology Fair to reach new heights

18 November 2024 | Story Nicolle Loader and Rudi Swart | Photo Supplied

The Centre for Mineral Biogeochemistry (CMBG) at the University of the Free State’s (UFS) support and partnership of the Tritech National Science and Technology Fair reached new heights this year with the event set to be featured in a new television series.

CMBG has been a proud sponsor and partner of the Tritech National Science and Technology Fair for the past four years. Established in 2008, Tritech is a renowned competition that allows Grade 7 to Grade 12 learners from across South Africa to showcase their research abilities. The Tritech National Science Competition serves as a beacon of opportunity for young minds, fostering their passion for scientific exploration and igniting their curiosity. It is designed to enhance scientific literacy, encourage innovation, and nurture the next generation of scientists and inventors.

“The CMBG has consistently demonstrated its commitment to promoting education and empowering young individuals. As a result, we have partnered with Tritech since 2021, and I believe that this partnership has opened new doors and possibilities for our young scientists. We are incredibly honoured to be part of such a dynamic and inspiring environment,” said Dr Mariana Erasmus, Vice Director: CMBG and Tritech EXCO member.

Power of science and technology

According to Dr Erasmus, at the CMBG, they believe in the power of science and technology to transform our world. Their involvement in this event aligns perfectly with the centre’s commitment to fostering innovation, encouraging critical thinking, and nurturing the next generation of scientists and innovators.

“We are excited about the opportunities Tritech presents to the university to engage with cutting-edge projects, to exchange ideas, and build lasting collaborations. The spirit of curiosity and exploration that Tritech embodies is exactly what drives our institution’s mission forward.”

In addition to assisting with the judging of projects during the National Science Competition at the Merensky Agricultural Academy in Tzaneen, the CMBG presents a fun but intellectually stimulating activity, showcasing various STEM-related disciplines that UFS offers to inspire students from across South Africa to celebrate scientific discovery. Each year, the CMBG collaborates with a different department for these activities, and this year, in October 2024, the collaboration was with the UFS Department of Chemistry.

‘Science Olympics’

The theme for Tritech 2024 was “Science Olympics”, and after the formalities of the project presentations were completed, the fair kicked off with a grand procession led by bearers of flaming torches and flags reminiscent of Olympic ceremonies. “Learners marched proudly, symbolising their commitment to science, with representatives from UFS and Tritech EXCO leading the way, an unforgettable visual display honoured the learners’ passion for exploration,” said Dr Erasmus.

The event transitioned into a video presentation explaining the misuse of performance-enhancing drugs in sports, followed by interactive activities focused on analysing possible doping agents. Thereafter, the UFS team guided learners through hands-on experiments, demonstrating the science behind identifying performance-enhancing drugs. Through engaging, real-world applications, learners were not only able to detect these substances but quantify their findings, making the learning experience both fun and educational.

As the night closed, the Chemistry team mesmerised the audience with a ‘magic show’. Explosions of colour, booming sounds, and flashes of light filled the sky, leaving everyone in awe. The show combined entertainment and chemistry, showcasing the wonders of science through spectacular reactions.

On TV

The fair concluded the next day with activities like kart building and livestock showcases, ending with a prize-giving ceremony to reward the learners for their hard work throughout the year. Adding to the excitement, the event is set to be featured in a new television series, with the pilot episode filmed during the weekend of Tritech Nationals 2024.

“The series promises to bring the Tritech experience to life for a wider audience, aiming to capture the incredible spirit, creativity, and innovation that defines Tritech. It will be an incredible opportunity to gain recognition, inspire others, and highlight the importance of science and technology in solving real-world challenges,” Dr Erasmus concluded.

This year’s fair was a celebration of knowledge, creativity, and the endless possibilities of science, leaving a lasting impact on all who attended.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept